迈普医学 reported revenue of ¥0.19B for the period ended 2026-06-30, +20.3% year on year. Net income was ¥0.06B, a 29.8% net margin on a 79.0% gross margin. The largest revenue line is 植入医疗器械 at 95% of the total. Free cash flow for the period was ¥0.03B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.19B | +20.3% |
| Gross profit | ¥0.15B | — |
| Operating income | ¥0.07B | — |
| Net income | ¥0.06B | +19.6% |
| Gross margin | 79.0% | Net margin 29.8% |
| Revenue Q/Q | +42.2% | — |
| Segment | Revenue | Share |
|---|---|---|
| 植入医疗器械 | ¥0.18B | 95.1% |
| 技术服务及其他 | ¥0.01B | 2.8% |
| 房屋租赁 | ¥0.00B | 1.7% |
| 3D打印设备 | ¥0.00B | 0.4% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.04B | 21.0% |
| R&D | ¥0.02B | 9.6% |
| SG&A | ¥0.07B | 34.6% |
| Tax & other | ¥0.01B | 5.6% |
| Item | Amount |
|---|---|
| Total assets | ¥0.90B |
| Total liabilities | ¥0.09B |
| Shareholders' equity | ¥0.81B |
| Equity / assets | 90.0% |
| Operating cash flow | ¥0.05B |
| Capital expenditure | ¥0.01B |
| Free cash flow | ¥0.03B |
| Cash conversion (OCF / net income) | 85% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
润丰股份 ・ 双乐股份 ・ 保立佳 ・ 深水规院 ・ 中集车辆 ・ 中环海陆 ・ 金百泽 ・ 安联锐视 ・ 绿岛风 ・ 天禄科技 ・ 能辉科技 ・ 义翘神州
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies